+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.

Age: 18Years +All GendersPhase 3
366 locations
R

Actively Recruiting

Researchers are investigating treatments for participants with unresectable stage III Non-small Cell Lung Cancer NSCLC who have completed platinum-based concurrent chemoradiation therapy without disease progression. This Phase 3 randomized study compares the effects of two drugs, Pumitamig and Durvalumab, to evaluate their impact on progression-free survival and other clinical outcomes over several years. The trial is sponsored by Bristol-Myers Squibb and aims to better understand treatment options after initial chemoradiation. Participants are randomly assigned to receive either Pumitamig or Durvalumab monotherapy, each given at specified doses on specified days. The study treatment follows completion of concurrent chemoradiotherapy, with no masking or placebo involved. The trial includes an observation period lasting up to three years for primary outcome measures and extends up to approximately nine years for overall survival monitoring. During the study, participants will undergo regular assessments to monitor progression-free survival based on standardized imaging criteria, along with evaluations of overall survival, response rates, disease control, and treatment duration. These assessments are conducted by blinded independent reviewers and investigators. Participants will be monitored closely for safety and treatment effects throughout the trial, which spans several years from enrollment through long-term follow-up.

Age: 18Years +All GendersPhase 3
260 locations
C

Actively Recruiting

Researchers are evaluating how well Rina-S GEN1184 works compared to standard chemotherapy treatments chosen by a physician for women with recurrent or progressive endometrial cancer who have had prior therapy. This randomized, open-label Phase 3 study involves about 660 participants and aims to assess progression-free survival and overall survival over approximately three years. The study is sponsored by Genmab and focuses on treatment after platinum-based chemotherapy and PDL-1 therapy. Participants are randomly assigned to one of two groups one group receives Rina-S intravenously every three weeks, and the other receives one of two chemotherapy drugspaclitaxel on days 1, 8, and 15 every four weeks, or doxorubicin on day 1 every three weekschosen by the investigator before randomization. Treatment duration varies but typically lasts between 4 to 6 months. No participants receive placebo all receive an active drug. Throughout the study, participants will visit study sites regularly for treatment and monitoring. Researchers will conduct evaluations including imaging scans to assess tumor response, monitor health status and quality of life, and track any treatment-related side effects. These assessments will continue for up to about three years to measure outcomes like progression-free survival and overall survival, ensuring close safety monitoring and comprehensive data collection during the participation period.

Age: 18Years +FEMALEPhase 3
178 locations
S

Actively Recruiting

Researchers are studying advanced or recurrent endometrial cancer that has a functioning mismatch repair system, called pMMR. This cancer type is harder for the immune system to attack. The study compares a new medicine, PF-08634404, combined with chemotherapy, against pembrolizumab plus chemotherapy. It aims to see if the new combination improves outcomes for women with this type of endometrial cancer. Participants receive intravenous infusions of their assigned treatment in cycles. One group receives PF-08634404 plus chemotherapy followed by PF-08634404 alone for up to 2 years, while the other group receives pembrolizumab plus chemotherapy followed by pembrolizumab alone for up to 2 years. About 600 adult women will be randomly assigned to these groups in an open-label design where both patients and doctors know the treatment. Participants attend regular visits for treatment and health assessments. Cancer response is checked every 9 weeks for about 2 years, then every 12 weeks afterward. Follow-up continues every 12 weeks by phone, in person, or health record review. Researchers measure progression-free survival, overall survival, treatment responses, safety, quality of life, and other health outcomes during and after treatment.

Age: 18Years +FEMALEPhase 3
54 locations
P

Actively Recruiting

Researchers are evaluating the new medicine PF-08634404 in combination with chemotherapy compared to the current standard treatment pembrolizumab with chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer NSCLC. The study includes adults with Stage IIIBIIIC or Stage IV squamous or non-squamous NSCLC who are not candidates for surgery or curative chemoradiotherapy and have not received prior treatment for advanced disease. Participants are assigned to two parts based on tumor type squamous NSCLC Part 1 or non-squamous NSCLC Part 2. Each participant is randomly assigned to receive either PF-08634404 or pembrolizumab with chemotherapy followed by maintenance therapy. Treatment is given through intravenous infusions in cycles, continuing as long as it is effective and safe. Different chemotherapy regimens are used depending on the tumor type. Throughout the study, participants attend regular visits for treatment and health monitoring. Cancer response is assessed every 6 weeks for the first 48 weeks and then every 12 weeks. Researchers will measure overall survival, progression-free survival, objective response rates, duration of response, adverse events, laboratory results, drug levels, immune response, and quality of life using questionnaires. The study lasts up to approximately 39 months with ongoing safety and effectiveness evaluations.

Age: 18Years +All GendersPhase 3
484 locations